NDA 205395 · Janssen Prods
Prezcobix
Cobicistat, Darunavir Ethanolate · Oral · Cytochrome P450 3A Inhibitor
Priority reviewLast checked: Nov 20, 2026Latest source record: Feb 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Jan 29, 2015
Approved uses
5
Original approval plus efficacy supplements
Registered trials
155
48 Phase 3, 6 recruiting
FAERS reports
1,762
1,152 serious, 136 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 1, 2026.
PREZCOBIX and PREZCOBIX PED are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) in treatment-naïve and treatment-experienced adults and pediatric patients 3 years of age and older weighing at least 15 kg with no darunavir resistance-associated substitutions (V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V, L89V) [see Use in Specific Populations (8.4) and Clinical Studies (14) ] . PREZCOBIX and PREZCOBIX PED are a two-drug combination of darunavir, a human immunodeficiency virus (HIV-1) protease inhibitor, and cobicistat, a CYP3A inhibitor, and are indicated for the treatment of HIV-1 in treatment-naïve and treatment-experienced adults and pediatric patients 3 years of age and older weighing at least 15 kg with no darunavir resistance-associated substitutions (V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V, L89V). ( 1 )
Mechanism: PREZCOBIX and PREZCOBIX PED are fixed-dose combinations of an HIV-1 antiviral drug, darunavir and a CYP3A inhibitor, cobicistat [see Microbiology (12.4) ].
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 27, 2026 Supplement 29 · Efficacy LetterLabel
- Mar 21, 2025 Supplement 28 · Efficacy LabelLetter
- Jul 31, 2020 Supplement 16 · Efficacy LetterLabel
- Jun 4, 2018 Supplement 9 · Efficacy · priority review LabelLetter
- Jan 29, 2015 Original approval · Type 4 - New Combination · priority review LabelReviewLetter
2 products under this application
- PREZCOBIX · COBICISTAT 150MG; DARUNAVIR ETHANOLATE EQ 675MG BASE · TABLET, ORAL · Prescription
- PREZCOBIX · COBICISTAT 150MG; DARUNAVIR ETHANOLATE EQ 800MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Cobicistat" as an intervention, any sponsor and status, largest first.
- RPV+DRV/Cobi Dual Therapy in Subjects With HIV Controlled InfectionPivotal-lookingStatus unknown
A.O. Ospedale Papa Giovanni XXIIIAcademic, hospital or other
NCT04064632 · 1,609 participants · Start Feb 1, 2017 · Primary completion Jun 13, 2019
Drug: Rilpivirine + darunavir/cobicistat · For: HIV Infection
Sites: Bergamo, Italy
- Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive ParticipantsPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT01815736 · 1,443 participants · Start Mar 27, 2013 · Primary completion Mar 16, 2015
Drug: E/C/F/TAF; E/C/F/TDF and 5 more · For: HIV; HIV Infections
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 167 sites in all
Janssen R&D IrelandJohnson & Johnson (Janssen) (JNJ)
NCT02269917 · 1,149 participants · Start Mar 2015 · Primary completion Feb 2017
Drug: D/C/F/TAF; Boosted Protease Inhibitor (bPI) and 1 more · For: Human Immunodeficiency Virus Type 1
Sites: Phoenix, Arizona; Bakersfield, California; Beverly Hills, California · 79 sites in all
- Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive AdultsPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT01797445 · 872 participants · Start Mar 12, 2013 · Primary completion Sep 19, 2014
Drug: E/C/F/TAF; E/C/F/TDF and 2 more · For: HIV; HIV Infections
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 117 sites in all
- Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive AdultsPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT01780506 · 872 participants · Start Dec 26, 2012 · Primary completion Aug 26, 2014
Drug: E/C/F/TAF; E/C/F/TDF and 2 more · For: HIV; HIV Infections
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 117 sites in all
Janssen Sciences Ireland UCJohnson & Johnson (Janssen) (JNJ)
NCT02431247 · 725 participants · Start Jul 6, 2015 · Primary completion Mar 2, 2017
Drug: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC; DRV/COBI FDC and 4 more · For: Immunodeficiency Virus Type 1, Human
Sites: Birmingham, Alabama; Phoenix, Arizona; Bakersfield, California · 80 sites in all
- Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive AdultsPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT01106586 · 708 participants · Start Apr 2010 · Primary completion Sep 2011
Drug: Stribild; ATV and 6 more · For: HIV; HIV Infections
Sites: Phoenix, Arizona; Little Rock, Arkansas; Beverly Hills, California · 146 sites in all
- Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive AdultsPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT01095796 · 707 participants · Start Mar 2010 · Primary completion Aug 2011
Drug: Stribild; Atripla and 2 more · For: HIV; HIV Infections
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 102 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pain440
- emotional distress426
- anxiety404
- anhedonia377
- chronic kidney disease256
- osteoporosis181
- bone density decreased170
- renal failure170
- depression147
- economic problem138
- fatigue135
- acute kidney injury131
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2015 | 69 |
| 2016 | 111 |
| 2017 | 194 |
| 2018 | 211 |
| 2019 | 289 |
| 2020 | 284 |
| 2021 | 170 |
| 2022 | 123 |
| 2023 | 113 |
| 2024 | 97 |
| 2025 | 65 |
| 2026 | 35 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Prezcobix (Darunavir/Cobicistat)
2024 spending
$255M
Beneficiaries
11,230
99,872 claims
Per beneficiary
$22,742
$81.22 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $268,321,186 |
| 2021 | $261,899,585 |
| 2022 | $265,352,859 |
| 2023 | $271,838,024 |
| 2024 | $255,398,075 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial.
Ryan P, Blanco JL, Masia M, et al. · Lancet HIV 2025 · Multicenter Study, Randomized Controlled Trial
- Symtuza® in clinical practice.
Luis Casado J, Fontecha M, Monsalvo M, et al. · Enferm Infecc Microbiol Clin (Engl Ed) 2018 · Clinical Trial, Phase III
- Pharmacokinetic boosting of olaparib: A randomised, cross-over study (PROACTIVE-study).
Overbeek JK, Guchelaar NAD, Mohmaed Ali MI, et al. · Eur J Cancer 2023 · Randomized Controlled Trial, Multicenter Study
- The Drug-Drug Interaction Profile of Presatovir.
Xin Y, Weng W, Murray BP, et al. · J Clin Pharmacol 2018 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Population Pharmacokinetics of Boosted-Elvitegravir in HIV-Infected Patients.
Custodio JM, Gordi T, Zhong L, et al. · J Clin Pharmacol 2016 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis.
Gantner P, Hessamfar M, Souala MF, et al. · Clin Infect Dis 2020 · Clinical Trial, Research Support, Non-U.S. Gov't
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.